The first total and unequivocal syntheses of (R)- and (S)-norneoenactin A (1), an analog of the antifungal antibiotic neoenactin A, are described. The key step of each synthesis was the Michael addition of a serinehydroxamate (5 or 8) to the appropriate vinyl ketone 4. Biological activity of the two enantiomers of norneoenactin A ((S)-1 and (R)-1) against Escherichia coli and several fungi has been investigated.
LINEAR PEPTIDE ANTIBIOTICS
申请人:RQX Pharmaceuticals, Inc.
公开号:US20170275334A1
公开(公告)日:2017-09-28
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
US9708368B2
申请人:——
公开号:US9708368B2
公开(公告)日:2017-07-18
[EN] LINEAR PEPTIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES À PEPTIDE LINÉAIRE
申请人:RQX PHARMACEUTICALS INC
公开号:WO2013123456A1
公开(公告)日:2013-08-22
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
In Silico Design and Enantioselective Synthesis of Functionalized Monocyclic 3‐Amino‐1‐carboxymethyl‐β‐lactams as Inhibitors of Penicillin‐Binding Proteins of Resistant Bacteria
novel class of monocyclic 3‐amino‐β‐lactams to inhibit penicillin‐bindingproteins (PBPs) of various (resistant) bacteria was assessed, revealing the potential of α‐benzylidenecarboxylates as interesting leads in the pursuit of novel PBP inhibitors. No deactivation by representative enzymes belonging to the four β‐lactamase classes was observed, while weak inhibition of class C β‐lactamase P99 was demonstrated